Education
About Us
Working with TipRanks
Follow Us
Indivior PLC (GB:INDV)
LSE:INDV
INDV Stock Chart & Stats
Day’s Range― - ―
52-Week Range554.50p - 1,751.00p
Previous CloseN/A
Volume15.05K
Average Volume (3M)438.75K
Market Cap
£947.18M
Enterprise Value958.26M
Total Cash (Recent Filing)$319.00M
Total Debt (Recent Filing)$375.00M
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Apr 24, 2025EPS Estimate
17.65Last Dividend Ex-Date
Jun 16, 2016Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding124,655,860
10 Day Avg. Volume305,867
30 Day Avg. Volume438,753
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.87
Price to Cash Flow (P/CF)18.40
P/FCF Ratio13.50
Enterprise Value/Market Cap1.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.00
Enterprise Value/Ebitda11.14
Forecast
1Y Price Target
1,111.38pPrice Target Upside48.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Indivior News
PremiumCompany Announcements
Indivior PLC Sees Change in Major Holdings
PremiumCompany Announcements
Indivior Announces Executive Share Vesting Under Deferred Bonus Plan
PremiumCompany Announcements
Indivior PLC Publishes 2024 Annual Report
PremiumCompany Announcements
Indivior CEO Receives Conditional Share Award Under Deferred Bonus Plan
PremiumCompany Announcements
Madison Avenue Partners Increases Stake in Indivior PLC---
Bulls Say, Bears Say
Bulls Say
Financial ResilienceEven on reduced numbers, Indivior is seen as a business generating strong cash flows and trading at low market multiples, suggesting the market is overly discounting the prospects of Sublocade.
Market Growth PotentialThe vast majority of physicians expect the proportion of their patients using LAIs to increase substantially over the next 12 months and five years, implying a 2-3x increase for the current market.
Market PositionSublocade retains a dominant market share with approximately 80% share within the cohort for buprenorphine-based LAI and 60% share of LAI-naive patients.
Bears Say
Competitive PressureIndivior's second profit warning of 2024, confirming strengthening Brixadi competitive headwinds, prompts a significant reduction in estimates and recognition that market confidence has been dented.
Future Sales ImpactOngoing Brixadi competition and further destocking are expected to negatively impact Sublocade's sales in the coming quarters.
Revenue ChallengesProfit warning issued due to lower-than-expected Sublocade revenues, with significant competition from Brixadi in CJS markets impacting sales.
---
Options Prices
Currently, No data available
---
Ownership Overview
5.05% Insiders
3.55%
Mutual Funds
39.12% Other Institutional Investors
48.17% Public Companies and
Individual Investors
INDV FAQ
What was Indivior PLC’s price range in the past 12 months?
Indivior PLC lowest share price was 554.50p and its highest was 1751.00p in the past 12 months.
What is Indivior PLC’s market cap?
Indivior PLC’s market cap is £947.18M.
When is Indivior PLC’s upcoming earnings report date?
Indivior PLC’s upcoming earnings report date is Apr 24, 2025 which is in 30 days.
How were Indivior PLC’s earnings last quarter?
Indivior PLC released its earnings results on Feb 20, 2025. The company reported 0.248p earnings per share for the quarter, beating the consensus estimate of 0.172p by 0.076p.
Is Indivior PLC overvalued?
According to Wall Street analysts Indivior PLC’s price is currently Undervalued.
Does Indivior PLC pay dividends?
Indivior PLC pays a Notavailable dividend of 36.495p which represents an annual dividend yield of N/A. See more information on Indivior PLC dividends here
What is Indivior PLC’s EPS estimate?
Indivior PLC’s EPS estimate is 17.65.
How many shares outstanding does Indivior PLC have?
Indivior PLC has 124,655,860 shares outstanding.
What happened to Indivior PLC’s price movement after its last earnings report?
Indivior PLC reported an EPS of 0.248p in its last earnings report, beating expectations of 0.172p. Following the earnings report the stock price went down -15.668%.
Which hedge fund is a major shareholder of Indivior PLC?
Currently, no hedge funds are holding shares in GB:INDV
---
Indivior Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
1,111.38p (48.09% Upside)
1,111.38p (48.09% Upside)
Blogger Sentiment
Bullish
GB:INDV Sentiment 70%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth £980.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.26%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-30.98%
Trailing 12-Months
Company Description
Indivior PLC
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC has research collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
---
INDV Stock 12 Month Forecast
Average Price Target
1,111.38p
▲(48.09% Upside)
Technical Analysis
Best Analysts Covering INDV
1 Year
1 Year Success Rate
9/25 ratings generated profit
1 Year Average Return
-24.23%
reiterated a buy rating 28 days ago
Copying James Vane's trades and holding each position for 1 Year would result in 36.00% of your transactions generating a profit, with an average return of -24.23% per trade.
---